Deep brain stimulation (DBS) can help to alleviate some urinary symptoms — such as urinary frequency, urgency, and incontinence — in Parkinson’s patients, and is particularly helpful to women, a large study reports. The study, “Clinical study of the effects of deep brain stimulation on urinary dysfunctions in…
Insoluble alpha-synuclein protein has long been thought to be the main component of Parkinson’s hallmark Lewy bodies, but researchers have now reported these abnormal aggregates are also made of cell membrane fragments, fat-like substances, and other cellular components. This finding was reported in a study, “Lewy pathology in…
Delivering a compound called nicotinamide adenine dinucleotide to the striatum, a key brain region involved in motor control, can ease Parkinson’s symptoms and reduce dopamine-producing neuronal loss in a mouse model of the disease, a study finds. The study, “Protective effects of β-nicotinamide adenine dinucleotide against motor…
Enterin Inc has enrolled the first patient in its Phase 1b DEMET clinical trial investigating the effectiveness, safety and tolerability of small molecule ENT-01 to treat Parkinson’s disease dementia. Contacts and locations of participating sites can be found here. Many neurodegenerative disorders involve aggregation of misfolded (harmful)…
VistaGen Therapeutics’ candidate, AV-101, reduced levodopa-induced dyskinesia (abnormal involuntary movements) while maintaining levodopa activity in a non-human primate model of Parkinson’s disease. Importantly, AV-101 treatment did not cause the adverse side effects observed with amantadine, a therapy that works similar to AV-101 to ease Parkinson’s symptoms.
N-acetyl-cysteine (NAC), a compound that is used by the body to produce an antioxidant called glutathione, may improve dopamine function and ease Parkinson’s disease symptoms, researchers report. Their study, “N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson’s Disease” was published in Clinical Pharmacology & Therapeutics. Low…
Not getting enough sleep may cause memory defects and emotional changes in Parkinson’s disease due to changes in dopamine metabolism, according to a study of zebrafish. The study, “Sleep Deprivation caused a Memory Defects and Emotional Changes in a Rotenone-based Zebrafish Model of Parkinson’s Disease,” was published in…
Osaka University scientists have built short fragments of DNA that can stop the production of abnormal alpha-synuclein protein in the brain — which may advance the development of new therapies for the control and prevention of Parkinson’s disease. The study, “Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting…
A molecule called anle138b was able to reduce toxic alpha-synuclein aggregates, or clumps, in the brain — a key event linked to Parkinson’s — and reverse motor symptoms associated with the disease in a novel Parkinson’s mouse model. The study, “Depopulation of dense α-synuclein aggregates is associated…
Japanese researchers have reported that zonisamide — an antiparkinsonian medicine approved in Japan as a combination therapy with levodopa — may be associated with a lower risk of dementia, insomnia, and gastric ulcers in Parkinson’s disease, compared with other non-levodopa medicines. Their research was published in the…
Get regular updates to your inbox.